Amitozyn impairs chromosome segregation and induces apoptosis via mitotic checkpoint activation

PLoS One. 2013;8(3):e57461. doi: 10.1371/journal.pone.0057461. Epub 2013 Mar 7.

Abstract

Amitozyn (Am) is a semi-synthetic drug produced by the alkylation of major celandine (Chelidonium majus L.) alkaloids with the organophosphorous compound N,N'N'-triethylenethiophosphoramide (ThioTEPA). We show here that the treatment of living cells with Am reversibly perturbs the microtubule cytoskeleton, provoking a dose-dependent cell arrest in the M phase. Am changed the dynamics of tubulin polymerization in vitro, promoted the appearance of aberrant mitotic phenotypes in HeLa cells and induced apoptosis by the activation of caspase-9, caspase-3 and PARP, without inducing DNA breaks. Am treatment of HeLa cells induced changes in the phosphorylation of the growth suppressor pRb that coincided with maximum mitotic index. The dose-dependent and reversible anti-proliferative effect of Am was observed in several transformed cell lines. Importantly, the drug was also efficient against multidrug-resistant, paclitaxel-resistant or p53-deficient cells. Our results thus open the way to further pre-clinical evaluation of Am.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Apoptosis / drug effects*
  • Benzophenanthridines / chemistry
  • Benzophenanthridines / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Chromosome Segregation / drug effects*
  • DNA Breaks, Double-Stranded / drug effects
  • HeLa Cells
  • Humans
  • M Phase Cell Cycle Checkpoints / drug effects*
  • Organothiophosphorus Compounds / chemistry
  • Organothiophosphorus Compounds / pharmacology*
  • Phenotype
  • Protein Multimerization / drug effects
  • Retinoblastoma Protein / metabolism
  • Signal Transduction / drug effects
  • Tubulin / chemistry
  • Tubulin / metabolism

Substances

  • Antineoplastic Agents, Phytogenic
  • Benzophenanthridines
  • Organothiophosphorus Compounds
  • Retinoblastoma Protein
  • Tubulin

Grants and funding

This study was in part supported by CNRS (France), by the Gefluc Association (France) and by the Academy of Young Scientists of Ukraine (Grant 4791/05). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.